Secures Funding

ReNeuron Group plc
24 January 2007

  ReNeuron secures funding from Michael J. Fox Foundation for ReN004 stem cell
                        therapy for Parkinson's disease

Guildford, UK, 24 January 2007: ReNeuron Group plc (LSE: RENE) today announces
that it has been awarded a grant from the US-based Michael J. Fox Foundation for
Parkinson's Research (MJFF) to develop its ReN004 stem cell therapy for
Parkinson's disease. The award was made under MJFF's Therapeutics Development
Initiative, designed to catalyse and expand industry investment in pre-clinical
Parkinson's drug development.

ReNeuron has previously presented data showing that its ReN004 candidate stem
cell lines have the potential to reverse the neurological deficits in
pre-clinical models of Parkinson's disease.  The data indicated good in vivo
survival of the cell lines and expression of the appropriate markers for
dopaminergic neurons, the cell type deficient in Parkinson's patients.  The MJFF
grant will allow ReNeuron to build on this pre-clinical data and also develop a
biodegradable delivery matrix which the Company believes will be required to
successfully implant the required cell type into Parkinson's patients.  The
grant will fund the ReN004 programme over the next year, accelerating its
progress towards the clinic.

In addition to its Parkinson's disease programme, ReNeuron has recently filed
for approval to commence initial clinical studies in the US with its lead ReN001
stem cell therapy for stroke.  The Company is also developing stem cell
therapies for Huntington's disease, Type 1 diabetes and diseases of the retina.

Michael Hunt, Chief Executive Officer of ReNeuron, said:

'We are delighted to have secured this important first grant for our ReN004
therapy from such a pre-eminent and high-profile US grant-awarding body
supporting research into Parkinson's disease.  Significantly, we regard this
award as an important independent validation of the therapeutic approach we are
adopting in seeking to address this debilitating disease.  Our ReN004
Parkinson's disease programme applies ReNeuron's platform c-mycERTAM cell
expansion technology to a further significant area of unmet medical need.'

Enquiries:

ReNeuron
Michael Hunt, Chief Executive Officer                    Tel: [phone]
Dr John Sinden, Chief Scientific Officer

Financial Dynamics
David Yates                                              Tel: [phone]
Nicola Daley

Notes to Editors

About Parkinson's disease

Parkinson's disease is a progressive neurodegenerative disease of the basal
ganglia region of the brain, with tremor, rigidity and difficulty initiating
movement being the most common symptoms.  The condition is associated with a
deficiency of the chemical dopamine in the brain.  It is estimated that four
million people worldwide have Parkinson's disease and there is currently no
effective cure.

The worldwide market for Parkinson's disease treatments is currently worth
approximately US$2.5 billion, and is dominated by drugs that manage the symptoms
of the disease, primarily by raising the level of dopamine in the brain.  These
drugs do not stop the progression of the disease, however, and are poorly
tolerated in many patients.

About Michael J. Fox Foundation for Parkinson's Research

The Michael J. Fox Foundation for Parkinson's Research is a US-based
organisation dedicated to ensuring the development of a cure for Parkinson's
disease within this decade through an aggressively funded research agenda.  The
Foundation has funded over $90 million in research to date, either directly or
through partnerships.  The Foundation's Therapeutics Development Initiative has
provided US$4.6 million in funding to drive industry programmes focused on
translational research into Parkinson's disease.

Further information about MJFF can be found at www.michaeljfox.org.

About ReNeuron

ReNeuron is a leading, UK-based adult stem cell therapy business.  It is
applying its novel stem cell platform technologies in the development of
ground-breaking stem cell therapies to serve significant and unmet or poorly-met
clinical needs.

ReNeuron has used its c-mycERTAM technology to generate genetically stable
neural stem cell lines.  This technology platform has multi-national patent
protection and is fully regulated by means of a chemically-induced safety
switch.  Cell growth can therefore be completely arrested prior to in vivo
implantation.

ReNeuron has filed for approval to commence initial clinical studies in the US
with its lead ReN001 stem cell therapy for chronic stroke disability.  This
represents the world's first such filing concerning a neural stem cell treatment
for a major neurological disorder.  ReNeuron has also generated pre-clinical
efficacy data with its ReN005 stem cell therapy for Huntington's disease, a
genetic and fatal neurodegenerative disorder that affects around 1 in 10,000
people.  This programme is in pre-clinical development.  In addition to its
stroke and Huntington's disease programmes, ReNeuron is developing stem cell
therapies for Parkinson's disease, Type 1 diabetes and diseases of the retina.

ReNeuron has also leveraged its stem cell technologies into non-therapeutic
areas - its ReNcellTM range of cell lines for use in research and in drug
discovery applications in the pharmaceutical industry.  ReNeuron's ReNcellTM CX
and ReNcellTM VM neural cell lines are marketed worldwide under license by
Millipore Corporation.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.

Further information on ReNeuron and its products can be found at
www.reneuron.com.

Data sources: MJFF; UK Parkinson's Disease Society; UK Stroke Association;
American Stroke Association.

This announcement contains forward-looking statements with respect to the
financial condition, results of operations and business achievements/performance
of ReNeuron and certain of the plans and objectives of management of ReNeuron
with respect thereto. These statements may generally, but not always, be
identified by the use of words such as 'should', 'expects', 'estimates',
'believes' or similar expressions. This announcement also contains
forward-looking statements attributed to certain third parties relating to their
estimates regarding the growth of markets and demand for products. By their
nature, forward-looking statements involve risk and uncertainty because they
reflect ReNeuron's current expectations and assumptions as to future events and
circumstances that may not prove accurate.  A number of factors could cause
ReNeuron's actual financial condition, results of operations and business
achievements/performance to differ materially from the estimates made or implied
in such forward-looking statements and, accordingly, reliance should not be
placed on such statements.

The terms 'ReNeuron', 'the Company' or 'the Group' used in this statement refer
to ReNeuron Group plc and/or its subsidiary undertakings, depending on the
context.


                      This information is provided by RNS
            The company news service from the London Stock Exchange